Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.16 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 2:10 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PBT) Snapshot

Open
A$0.16
Previous Close
A$0.16
Day High
A$0.16
Day Low
A$0.16
52 Week High
09/5/14 - A$0.36
52 Week Low
02/25/15 - A$0.14
Market Cap
85.4M
Average Volume 10 Days
148.2K
EPS TTM
A$-0.02
Shares Outstanding
533.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRANA BIOTECHNOLOGY LTD (PBT)

Related News

No related news articles were found.

prana biotechnology ltd (PBT) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd (PBT) Details

Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate includes PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds, which support new therapies for the treatment of neurodegenerative disease and other highly prevalent conditions. The company was founded in 1997 and is based in Parkville, Australia.

12 Employees
Last Reported Date: 11/3/14
Founded in 1997

prana biotechnology ltd (PBT) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$444.4K
Chief Operating Officer
Total Annual Compensation: A$324.8K
Company Secretary
Total Annual Compensation: A$50.0K
Compensation as of Fiscal Year 2014.

prana biotechnology ltd (PBT) Key Developments

Prana Biotechnology Announces Safety Outcomes of Alzheimer's IMAGINE Extension Trial

Prana Biotechnology announced the safety outcomes of the IMAGINE Extension study in patients with Alzheimer's disease. A 250mg dose of PBT2 was safe and well tolerated over a 2 year period. The independent Data Safety Monitoring Board did not identify any safety concerns related to PBT2. The IMAGINE Extension Study allowed all 40 participants who completed the original 12 month IMAGINE trial to receive PBT2 for a further 12 months. In all, 33 out of the 40 eligible IMAGINE patients elected to continue onto the Extension study. It was an Open Label study, with all participants taking PBT2. A total of 27 patients completed the Extension Study. Clinical and scientific experts are reviewing the effects of PBT2 taken for 2 years. Whilst there is no placebo group to compare to within the Extension Study, the experts are very interested in better understanding how treatment with PBT2 would differ from the anticipated outcome without treatment. The safety data will form part of the package presented to the FDA as part of goal to remove the Partial Clinical Hold on PBT2 in the US. Prana will continue to work with the US Food and Drug Administration and other agencies to initiate a Phase 3 trial for PBT2 to treat Huntington disease. PBT2 for the treatment of Huntington disease was recently granted Orphan designation in Europe and was granted Orphan designation in the US in 2014.

Prana Biotechnology Limited Announces the European Commission Approves the Orphan Designation for PBT2 for the Treatment of Huntington's Disease

Prana Biotechnology Limited announced that the European Commission has approved orphan designation for PBT2 for the treatment of Huntington's disease, stating that Prana has shown that PBT2 might be of significant benefit for patients with Huntington's disease. The approval was based on the recommendation of a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The COMP assessed the scientific documentation for PBT2 against the key criteria for orphan designation. The criteria require that PBT2 be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating; have a prevalence in the EU not more than five in 10,000, and no satisfactory method of diagnosis, prevention or treatment of the condition concerned, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation provides for ten years of market exclusivity in the European Union (EU) from the granting of a marketing authorization (approval for sale). Other benefits relate to assistance in developing clinical protocols, reduced fees, and access to EU-funded research grants.

Prana Biotechnology Limited Reports Consolidated Cash Flow Results for the Third Quarter and Nine Months Ended March 31, 2015

Prana Biotechnology Limited reported consolidated cash flow results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net operating cash flows (carried forward) of AUD 4,360,000 and payment for acquisition of physical non-current assets of AUD 4,000. For the nine months, the company reported net operating cash flows (carried forward) of AUD 12,783,000 and payment for acquisition of physical non-current assets of AUD 26,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBT:AU A$0.16 AUD 0.00

PBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBT.
View Industry Companies
 

Industry Analysis

PBT

Industry Average

Valuation PBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit www.pranabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.